Wednesday, 28 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Merger & Restructuring

Thyrocare Technologies Merger & Restructuring Worth ₹141.4 Cr

Thyrocare's board approved sale of 100% in Nueclear Healthcare to Trovera for ~₹141.40 Crore. The move exits radiology to refocus on core pathology business.

Key figures
Value₹141.4 Cr
Execution periodOn or before November 30, 2026
Source

BSE filing, NSE: THYROCARE. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Thyrocare Technologies Ltd: key numbers

Share price
₹494.50
Market cap
₹7,871 Cr
Revenue (annual)
₹829.0 Cr
Net profit (annual)
₹163.0 Cr
P/E (TTM)
44.6×Sector 52.0×
Promoter holding
51.02%-9.90% QoQ
FII holding
9.37%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Thyrocare Technologies Ltd

All →

Other merger & restructuring announcements

All →
19:53 IST NSE
Merger & RestructuringEmkay Global Financial Services Ltd EMKAY

Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr

Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.

Value
₹30.00 Cr
Execution
Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals